Phenoxybenzamine hydrochloride

SKU: orb1309567

Description

Phenoxybenzamine hydrochloride

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 63-92-3
• MW: 340.3
• Purity: 98.04%
• Formula: C₁₈H₂₃Cl₂NO
• SMILES: Cl.CC(COc1ccccc1)N(CCCl)Cc1ccccc1
• Target: Adrenergic Receptor,CaMK
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.88 mM);DMSO:250 mg/mL (734.65 mM);Ethanol:63 mg/mL (185.13 mM);H2O:14 mg/mL (41.14 mM)

Bioactivity

• In Vivo:
  Phenoxybenzamine hydrochloride (20 nM, s.c.) effectively suppresse the tumorigenesis of glioma cells in mice an the cell density in Phenoxybenzamine hydrochloride-U87 mg xenografts decreases significantl. Phenoxybenzamine hydrochloride (1 mg/kg, i.v.) treated rats shows significant improvements in NSS and foot fault scorin .
• In Vitro:
  The IC50 (100 nM) derived fro the blockade of [3H]yohimbine binding by Phenoxybenzamine hydrochloride is significantly less tha the IC50 (550 nM) fo the corresponding reversal by Phenoxybenzamine hydrochloride o the effects of norepinephrine on cyclic AMP accumulatio. Phenoxybenzamine hydrochloride (50 nM) in conbination with Phenoxybenzamine hydrochloridetolamine (1000 nM) enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with pretreatment with Phenoxybenzamine hydrochloride (50 nM) alone in endothelium-intact aortae. Combined treatment with either dexmedetomidine (300 or 1000 nM) and Phenoxybenzamine hydrochloride (50 nM) or Phenoxybenzamine hydrochloridetolamine (1000 nM) and Phenoxybenzamine hydrochloride (50 nM) enhance Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with Phenoxybenzamine hydrochloride alone (50 nM). In addition, combined treatment with Phenoxybenzamine hydrochloridetolamine and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride combined treatment. Combined treatment with high concentration of dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with combined treatment with low concentration of dexmedetomidine (300 nM) and Phenoxybenzamine hydrochlorid.
• Cell Research:
  Phenoxybenzamine hydrochloride is dissolved in DMSO. After cytometry, × cells are implanted in a 96-well plate in 100 μL DMEM supplemented with 10 % FBS. Ten microliter (10 % o the total volume) WST-1 (Water Soluble Tetrazolium) is added to cells and incubated at 37℃or 30 min before colorimetric assay with 450 nM excitation and 630 nM emission at 24 h intervals up to 96 h the mean fluorescence value is counted, an the cell number is determined usin the s andard curve.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AdrenergicReceptor, Adrenergic Receptor, CAM, antitumor, Beta Receptor, glioma, hypertension, Inhibitor, NSC 37448, inhibit, NCI-c01661, neuroprotective, NSC37448, NSC-37448, pheochromocytoma, Phenoxybenzamine, Phenoxybenzamine HCl, Phenoxybenzamine hydrochloride, Phenoxybenzamine Hydrochloride, α-adrenergic receptor

Compound Identifiers

PubChem CID

5284441